Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line chemotherapy with or without bevacizumab after prior first-line bevacizumab in platinum-sensitive recurrent ovarian cancer
2012-004362-17Phase 3Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in ovarian cancer, sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Started Dec 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2012-004362-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004362-17.